Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylstilbestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 14/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 11/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylstilbestrol SCHEMBL27372002 | 1.00 | ESR1 (1.00) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL9224 | 1.00 | ESR1 (1.00) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL9223 | 1.00 | ESR1 (1.00) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL28317397 | 0.97 | ESR1 (0.95) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL27619582 | 0.97 | ESR1 (0.95) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL28180301 | 0.97 | ESR1 (0.95) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL17594535 | 0.97 | ESR1 (0.95) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL11333418 | 0.97 | ESR1 (0.95) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL21351798 | 0.97 | ESR1 (0.95) | ESR1ESR2NR1I2CYP1A2CYP3A4 | |
| Diethylstilbestrol SCHEMBL27692822 | 0.97 | ESR1 (0.95) | ESR1ESR2NR1I2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100828-A1 | NOVEL IONIZABLE LIPID AND LIPID NANOPARTICLE COMPOSITION USING SAME | 주식회사 메디치바이오 | 2025-05-15 | — | — | WO | claimed |
| WO-2025100828-A1 | NOVEL IONIZABLE LIPID AND LIPID NANOPARTICLE COMPOSITION USING SAME | 주식회사 메디치바이오 | 2025-05-15 | — | — | WO | disclosed |
| US-20140248634-A1 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140248634-A1 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013019655-A2 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010068710-A2 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-0740708-B1 | DESIGN OF DRUGS INVOLVING RECEPTOR-LIGAND-DNA INTERACTIONS | HENDRY LAWRENCE B (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20020064790-A1 | Design of drugs involving receptor-ligand-DNA interactions | HENDRY LAWRENCE B (US) | 2002-05-30 | — | — | US | disclosed |
| US-6306595-B1 | Design of drugs involving receptor-ligand-DNA interactions | CLARIANT AZ (DEUTSCHLAND) AKTIENGESELLSCHAFT (DE) | 2001-10-23 | — | — | US | disclosed |
| US-5888738-A | Design of drugs involving receptor-ligand-DNA interactions | HENDRY LAWRENCE B (US) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | JAK2, JAK1, JAK3 | ESR1 2332/4885ESR2 1394/4885NR1I2 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.